SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Arthur Ashe — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientArthur Ashe
Date of birth1943-07-10
IdentifiersMRN HR-ML013-SYN-TD; SSN (made up) 000-13-6620
Document date1989-04-13
AuthorVivian Tolliver, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month HIV and lipid review. [S]

History of Present Illness

Mr. Ashe returns three months after his first visit, about seven months after starting antiretroviral therapy. He has missed no doses. He has had no headache, weakness, rash, fever, or chest pain. He is coaching four afternoons a week and hitting balls three times a week without angina. He has had no muscle aches on atorvastatin and ezetimibe. His blood tests were drawn this morning. He left before giving a urine sample, so the urine albumin test ordered at the last visit was not done. He feels more like himself and says that worry about his privacy comes and goes. [S]

ElementDetail
AdherenceNo missed doses
ActivityCoaching four afternoons a week; tennis drills without angina
Side effectsNone
Urine testNot collected this morning

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or night sweats; weight up 1.2 kg
CardiovascularNegativeNo chest pain or palpitations
MusculoskeletalNegativeNo muscle aches
NeurologicalNegativeNo headache, seizure, or weakness
PsychiatricNegativeMood good; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesiumOne tablet by mouth once dailyOral route1988-09-25activeS
Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intakeThree tablets by mouth daily after a 200 mg loading doseOral route1988-09-11 to 1988-10-23completedS
Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intakeThree tablets by mouth every 6 hoursOral route1988-09-11 to 1988-10-23completedS
Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intakeTwo tablets by mouth dailyOral route1988-09-11 to 1988-10-23completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1988-10-23 to 1989-10-19completedS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1979-07-31activeS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1979-08-01activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1989-01-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route1979-08-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1989-04-13Body height185cmS
1989-04-13Body weight73.8kgS
1989-04-13Body mass index (BMI) [Ratio]21.6kg/m2S
1989-04-13Systolic blood pressure120mm[Hg]S
1989-04-13Diastolic blood pressure74mm[Hg]S
1989-04-13Heart rate68/minS
1989-04-13Respiratory rate14/minS
1989-04-13Body temperature36.7CelS
1989-04-13Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1989-04-13HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection0{copies}/mLBelow 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detectedNormalS
1989-04-13CD3+CD4+ (T4 helper) cells [#/volume] in Blood218/uL500-1500 /uLLowS
1989-04-13Leukocytes [#/volume] in Blood by Automated count4.610*3/uL4-11 10*3/uLNormalS
1989-04-13Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS
1989-04-13Platelets [#/volume] in Blood by Automated count22410*3/uL150-400 10*3/uLNormalS
1989-04-13Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1989-04-13Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
1989-04-13Creatinine [Mass/volume] in Serum or Plasma1.15mg/dL0.74-1.35 mg/dLNormalS
1989-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M80mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1989-04-13Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1989-04-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-56 U/LNormalS
1989-04-13Cholesterol [Mass/volume] in Serum or Plasma118mg/dL<=199 mg/dLNormalS
1989-04-13Cholesterol in HDL [Mass/volume] in Serum or Plasma41mg/dL>=40 mg/dLNormalS
1989-04-13Triglyceride [Mass/volume] in Serum or Plasma125mg/dL<=149 mg/dLNormalS
1989-04-13Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation52mg/dL<=99 mg/dLNormalS
1989-04-13Lipoprotein a [Mass/volume] in Serum or Plasma24mg/dL<=29 mg/dLNormalS
1989-04-13Hepatitis B virus surface Ab [Units/volume] in Serum86m[IU]/mL>=10 m[IU]/mLNormalS

Physical Exam

Vital signs recorded on 1989-04-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 73.8 kg, blood pressure 120/74
MouthNo thrush
CardiovascularRegular rhythm; no murmur; no edema
NeurologicalGrip and fine finger movements equal on both sides

Problems

ProblemClinical statusVerificationCodeProvenance
HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infectionactiveconfirmed B20S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled.
Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapyactiveconfirmed B58.2S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass.
Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1942 and 1946 operationsactiveconfirmed I25.10S — Synthetic modern diagnosis; the history remains D.
Old myocardial infarction at age 36activeconfirmed I25.2S — Synthetic coded history of the documented 1979 heart attack.
Hyperlipidemia, on high-intensity statinactiveconfirmed E78.5S — Synthetic diagnosis; no cholesterol value from his lifetime is used.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHIV-1 viral load4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 monthsCompleted todayNot detected (below 20 copies/mL), from 42 three months ago
LaboratoryCD4 countEvery 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ARTCompleted today218 cells/uL, above 200 for the first time
Medication safetyART adherence and drug-interaction review (antacids, calcium, iron, new medicines)Every visitCompleted todayNo missed doses; no interacting medicines
LaboratoryComplete blood countEvery 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ARTCompleted todayHemoglobin 13.6 g/dL, white cells 4.6, platelets 224
LaboratoryPotassium, creatinine, and eGFR1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 monthsCompleted todayPotassium 4.7 mmol/L, creatinine 1.15 mg/dL, eGFR 80
LaboratoryUrine albumin-to-creatinine ratio on tenofovirAt the start of tenofovir and yearlyDeferredOrdered after the deviation recorded at the four-week visit, but the sample was not collected this morning: a second miss. Creatinine is stable, so no harm is evident. Corrective action: the urine sample is now part of the standing order for each blood draw, starting at six months
LaboratoryALTEvery 6 months on ART; with symptoms on a statinCompleted todayALT 27 U/L
Medication safetyToxoplasma maintenance therapy and stopping criteriaContinue until CD4 above 200 for more than 6 months on ART with a suppressed viral loadCompleted todayCD4 above 200 for the first time; continue for at least six more months
Medication safetyPneumocystis prophylaxisWhile CD4 below 200; stop after more than 3 months above 200Completed todayCovered by the maintenance dose
ExaminationNeurological check: headache, seizure, weakness, and right-hand strengthEvery visitCompleted todayNo symptoms; strength equal
LaboratoryHepatitis B vaccine series and antibody checkTwo doses four weeks apart; surface antibody 1 to 2 months after the last doseCompleted todaySurface antibody 86 mIU/mL nine weeks after dose 2: protected
Self-managementMeningococcal ACWY vaccineTwo doses at least 8 weeks apart, then every 5 yearsCompleted todayDose 2 given today, thirteen weeks after dose 1; booster in five years
Self-managementRecombinant zoster vaccineTwo doses 2 to 6 months apart, from age 18 with HIVCompleted todayDose 1 given today
Self-managementPsychosocial support, disclosure on his terms, and U=U counselingEvery visitCompleted todayWorry about privacy comes and goes; U=U explained; peer support offered again
SurveyDepression screen (PHQ-9 or PHQ-2)At intake, at six months, and yearlyUp to datePHQ-9 5 at intake; mood good; next at six months
ExaminationBlood pressure (goal below 130/80)Every visitCompleted today120/74 mmHg
ExaminationWeight, BMI, and physical activityEvery visitCompleted today73.8 kg, BMI 21.6; regaining weight lost during his illness
Self-managementTobacco useEvery visitCompleted todayNever used tobacco
Medication safetyCoronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibeEvery visitCompleted todayTaking all three; no muscle aches
Self-managementAngina review and chest-pain planEvery visitCompleted todayNo angina with tennis drills; nitroglycerin not used
LaboratoryLipid panel4 to 12 weeks after a change, then every 3 to 12 months; yearly when stableCompleted todayLDL 52 mg/dL, at goal; drawn 13 weeks after the change, one week outside the window, with no effect on care
LaboratoryLipoprotein(a), once in adulthoodOnce in adulthoodCompleted today24 mg/dL, not elevated; no repeat needed
ImagingStress testing, coronary imaging, or echocardiographyOnly with new or worsening symptoms; routine surveillance not recommendedNot indicatedNo symptoms

Goal progress:

Immunizations given today: Meningococcal conjugate vaccine MenACWY, dose 2 of 2; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026)

Follow-up: Six-month visit with viral load, CD4 count, metabolic panel, urine albumin, and the PHQ-9. Results by secure message. Next scheduled visit 1989-07-13: six-month HIV and coronary disease review with depression screening. [S]